Biogen to Present Data at Alzheimer's Association International Conference® 2017 (AAIC®)
Biogen (NASDAQ: BIIB) will present data from its Alzheimer’s disease programs at the Alzheimer's Association International Conference® 2017 (AAIC®) in London, July 16 - 20, 2017.
The planned poster presentations include:
Change from Baseline in Clinical Dementia Rating Scale Cognitive
and Functional Domains in PRIME, a Randomized Phase 1b Study of the
Anti-Amyloid Beta Monoclonal Antibody Aducanumab (BIIB037). Poster
1-053: July 16, 2017, 9:30 a.m. GMT+1. This new post-hoc analysis
shows the change in the cognitive and functional subscores, which are
derived from the previously reported clinical dementia rating (CDR)
score for the overall and early Alzheimer’s disease populations in the
1, 3, 6 and 10 mg/kg aducanumab fixed-dosing cohorts in Phase 1b.
This poster will be available concurrently with the session on the Investors section of the Biogen company website, www.Biogen.com.
- Signs and Symptoms of Alzheimer’s Disease Noted in Health Records up to 5 Years Prior to Diagnosis . Poster 2-275: July 17, 2017, 9:30 a.m. GMT+1. This analysis reports the documentation of cognitive and behavioral impairment from U.S. medical health records, prior to an Alzheimer’s disease diagnosis.
Aducanumab (BIIB037) is an investigational compound being developed for the treatment of early Alzheimer’s disease. Aducanumab is a human recombinant monoclonal antibody (mAb) derived from a de-identified library of B cells collected from healthy elderly subjects with no signs of cognitive impairment or cognitively impaired elderly subjects with unusually slow cognitive decline using Neurimmune’s technology platform called Reverse Translational Medicine (RTM). Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement.
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology, and today the company has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. For more information, please visit www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook and YouTube.
Biogen Safe Harbor
This press release contains forward-looking statements, including statements relating to the development and potential benefits, safety and efficacy of investigational drugs, including aducanumab and results of certain clinical studies. These statements may be identified by words such as “believe,” “except,” “may,” “plan,” “potential,” “will” and similar expressions, and are based on our current beliefs and expectations. You should not place undue reliance on these statements or the scientific data presented. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. Factors which could cause actual results to differ materially from our current expectations include the risk that we may not fully enroll our clinical trials or enrollment will take longer than expected, unexpected concerns may arise from additional data or analysis, including data, analysis or results obtained during our clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates, or we may encounter other unexpected hurdles which may be impacted by, among other things, the occurrence of adverse safety events, failure to obtain regulatory approvals in certain jurisdictions, failure to protect intellectual property and other proprietary rights, product liability claims, third party collaboration risks, and the other risks and uncertainties that are described in the Risk Factors section of Biogen’s most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and we assume no obligation to update any forward-looking statement.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Funds Affiliated with Apollo Global Management and Apeiron Management Establish Partnership to Pursue Corporate Credit Investment Opportunities in Italy22.2.2018 17:00 | Tiedote
Funds affiliated with Apollo Global Management, LLC (together with its consolidated subsidiaries, “Apollo”) (NYSE: APO) today announced a strategic partnership with Apeiron Management SpA (“Apeiron”) to focus on investments in Italian corporate credit opportunities. The initiative targets innovative financing solutions for Italian corporate borrowers, and investments in impaired loans, claims, and other credit instruments tied to Italian companies, with the view to capitalizing on the country’s strong manufacturing base, ongoing banking reform, and improved bankruptcy legislation. The partnership will focus primarily on stressed and distressed opportunities, insolvency compositions, and non-performing corporate credit in Italy. Capital will be deployed via debt and equity investments in the EUR 5 million to EUR 50 million range, with the capacity to pursue larger transactions opportunistically. To accomplish these goals, Apollo has established Apollo Delos (“Delos”) as a dedicated inve
Mother Who Lost Infant Son to Medical Error to Join Panel at World Patient Safety, Science & Technology Summit22.2.2018 16:00 | Tiedote
New mother Deahna Visscher was feeling hopeful. Although her son Grant had been born with a heart defect, he was doing very well after surgery. Just 11-days old, doctors felt he could soon leave the hospital. But that didn’t happen. A nurse incorrectly inserted a feeding tube piercing the little infant’s trachea and filling his lungs with fluid. “The nurse asked me to go out into the hall and ask for help,” recalls Deahna. “I told them my son was turning blue and I watched as 20 staff members tried to resuscitate him. “ Grant was pronounced dead at 9:10 p.m. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180222005694/en/ Deahna Visscher will share her personal experience of losing her 11-day old son to a medical error. (Photo: Business Wire) Since that tragic night in 2008, Deahna Visscher has become a fierce patient advocate. The Patient Safety Movement Foundation (PSMF) is happy to announce her participation in a compelling
Mavenir Teams with Dell EMC to Deliver Expanded Cloud-Native NFV Solutions22.2.2018 16:00 | Tiedote
Mavenir, a leader in mobile network transformation, today announced its collaboration with Dell EMC OEM Solutions to deliver a broad range of solutions for service providers and enterprises covering 5G Cloud RAN, Packet Core, IoT, VoLTE, VoWiFi and RCS on Mavenir’s cloud-native Open Stack NFV and container CloudRange™ platform. Communications service providers are under intense pressure to simultaneously drive new revenue streams and aggressively reduce costs as OTTs gain market share in voice and messaging services. This expanded collaboration directly addresses these challenges, bringing together Mavenir’s extensive software stack for mobile network providers and Dell EMC solutions for infrastructure, cloud and IOT to create new offerings and best practices that enable the cost effective and rapid evolution of service provider and enterprise networks. Mavenir and Dell EMC OEM will pursue advanced engineering engagements in Cloud RAN, IOT and Enterprise Private LTE Solutions, includin
Westinghouse Electric Company Signs Cooperation Agreement for Lead-Cooled Fast Reactor Development22.2.2018 16:00 | Tiedote
Westinghouse Electric Company has signed a Cooperation Agreement for lead-cooled fast reactor (LFR) technology development with the Italian National Agency for New Technologies, Energy and Sustainable Economic Development (ENEA) and Ansaldo Nucleare. The agreement demonstrates each party’s commitment to collaborating toward the development of a next-generation nuclear plant based on LFR technology, which is both “walk-away” safe and economically competitive across global energy markets. “This agreement is an exciting step towards the development of a lead-cooled fast reactor for the marketplace,” said Ken Canavan, Westinghouse chief technology officer and vice president, Global Technology Office. “The LFR is game-changing technology for clean energy industries, and Westinghouse is pleased to be working with such experienced partners to bring this innovative concept to fruition.” Beyond baseload electricity generation, the high-temperature operation of the LFR will allow for a broad ran
Equifax Integrates Entersekt’s Digital Security System22.2.2018 15:35 | Tiedote
Entersekt, a leader in push-based authentication and mobile app security, today announced a technology partnership with global information solutions company Equifax Inc. (NYSE:EFX). Equifax has licensed Entersekt’s product Transakt to serve as an additional layer of security protecting the Equifax online and mobile services. Transakt empowers consumers to play an active role in safeguarding their digital identities and accounts. Whenever access to a digital identity or account is required, an authentication request is pushed to their phone or tablet in real time. They approve or block access by simply tapping Accept or Reject. It’s a highly intuitive, one-touch user experience engineered for a mobile-first world. Transakt’s ease of use belies its advanced set of security features. Covered by 56 patents in the United States and elsewhere, the digital-certificate–based technology uniquely identifies each registered mobile device; ensures its continued integrity as a factor of authenticat
Kite, a Gilead Company, and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for the Treatment of Cancer22.2.2018 15:00 | Tiedote
Kite, a Gilead Company (Nasdaq:GILD) and Sangamo Therapeutics, Inc. (Nasdaq:SGMO) today announced the companies have entered into a worldwide collaboration using Sangamo’s zinc finger nuclease (ZFN) technology platform for the development of next-generation ex vivo cell therapies in oncology. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180222005488/en/ Kite will use Sangamo’s ZFN technology to modify genes to develop next-generation cell therapies for autologous and allogeneic use in treating different cancers. Allogeneic cell therapies from healthy donor cells or from renewable stem cells would provide a potential treatment option that can be accessed directly within the oncology infusion center, thus reducing the time to infusion for patients. Under the terms of the agreement, Sangamo will receive an upfront payment of $150 million and is eligible to receive up to $3.01 billion in potential payments, aggregated across 10
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme